about
A multicenter evaluation of a new therapeutic plasma exchange procedure.Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature.Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration.Use of plasma exchange in patients with heparin-induced thrombocytopenia: a report of two cases and a review of the literature.Drug-associated thrombotic microangiopathies.Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR).Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR).Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.Congenital glioblastoma multiforme: a report of three cases and a review of the literature.Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention.Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.Frozen preoperative autologous blood donation for heart transplantation at the Mayo Clinic from 1988 to 1999.New directions in plasma exchange.Transfusion-related acute lung injury: incidence and risk factors.Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective studyFresh red blood cell transfusion and short-term pulmonary, immunologic, and coagulation status: a randomized clinical trial.Transfusion-related acute lung injury in the critically ill: prospective nested case-control study.Complications of donor apheresis.Clinical outcomes and mechanism of action for rheopheresis treatment of age-related macular degeneration (AMD).Therapeutic plasma exchange for perioperative management of patients with congenital factor XI deficiency.Category IV indications for therapeutic apheresis: ASFA fourth special issue.The new approach to assignment of ASFA categories--introduction to the fourth special issue: clinical applications of therapeutic apheresis.Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.Dermal and conjunctival melanocytic proliferations in diffuse uveal melanocytic proliferation.Lipid apheresis, indications, and principles.Apheresis medicine state of the art in 2010: American Society for Apheresis fifth special edition of the Journal of Clinical Apheresis.The potential role of plasma exchange as a treatment for bilateral diffuse uveal melanocytic proliferation: a report of two cases.Randomized controlled trials in therapeutic apheresis.Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue.The mechanisms of action of plasma exchange.The entity of immunoglobulin A-related anaphylactic transfusion reactions is not evidence based.Use of hydroxyethyl starch in leukocytapheresis procedures does not increase renal toxicity.How I treat autoimmune hemolytic anemia.Transfusion of apheresis PLTs from IgA-deficient donors with anti-IgA is not associated with an increase in transfusion reactions.Red cell exchange for a case of babesiosis.Comparison of hematopoietic progenitor cell collections using the COBE Spectra version 7 and Amicus version 3.1 for patients with AL amyloidosis.Apheresis instrument settings influence infused absolute lymphocyte count affecting survival following autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma: the need to optimize instrument setting and define a lympCost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.A factor found in the IgG fraction of serum of patients with paraneoplastic bilateral diffuse uveal melanocytic proliferation causes proliferation of cultured human melanocytes.
P50
Q30456588-67FAE707-578A-4BA6-98BA-71E02714FC77Q33383006-461296FD-285D-4883-BADF-B8ED80601767Q33384920-0007C0D8-B623-45D1-A6EB-DBED20394F48Q33388900-8381508E-2CD8-49A1-842C-3ACB7F2775B6Q33394975-F5A2F89C-AF8C-42AE-90F3-B9614ADC4FC9Q33403674-6D88C95C-0F21-49F4-BE5D-FF283D9DEF56Q33404125-3C4047BD-F328-4228-8A54-51283FD7E53FQ33406646-EF9D88C1-29E7-476B-BC8B-14453E02AABFQ34122035-FE37FD38-EB63-4045-A0C3-A6309D4D9E43Q34328433-F3163F78-BF5C-41C6-8B9F-E73FD47BDD49Q34490998-B883042D-7B86-42FB-9AFA-AE71D3137092Q35012436-41FC0F9F-027A-461D-9A83-4365B7B46DE1Q35093701-BC0456A1-4C76-4C9D-93A3-50DD91B6B0FBQ35561970-839B248F-F1C9-4535-B32E-5DB0DED30A81Q35777001-A467DBB4-B217-4E10-B9E8-4C2B84C249AEQ35827808-23799E1C-C59A-4DA1-8C1C-9C0DDBF905F0Q35988928-62083C9A-9DA7-470F-85D9-D50E74D45F83Q36102830-38CBB242-189D-4033-A011-CAE6D370CBACQ36119866-317F11F8-FF25-47A3-9B43-F5E8B65476B3Q36126231-6E68F8B0-93E4-4B71-B9EB-FBCECDF6FC7FQ36308588-00CC796C-3C28-4AA7-8DD1-267BFFA402F4Q36766561-8559D16F-9D1F-4BDF-A485-0DEB2EAC6877Q36774053-55129E53-E250-4F2C-BAF6-7A715F4E5956Q36774059-96217C8E-B063-49E8-8FCF-904BCFF64392Q37168824-22CC5E57-DA4F-4116-AE88-172109735BA2Q37915431-ECEDAE6B-E15F-4107-8BED-277C9F251616Q37924703-382CE11A-22FC-4922-9626-D5DDB01A1CAEQ37928579-0BD9A191-36CD-46A2-881F-C4315FC25E35Q38078306-46EE1C86-0311-47F5-B752-2AAFBCD5A912Q38122663-0B97942D-FBEB-44BC-B44C-E515CE04B920Q38156510-70F44BE7-AECD-481E-A80F-7A655D1ABC23Q38234399-71CC6DDA-6366-4A71-91FA-3D49922EF3B9Q38947834-FAC2EA44-4973-4A5D-A293-47F45E5A2D64Q39209508-DB2111CE-7DAA-4FE3-A121-38AB9BF6E731Q40539198-9B1833D5-CDD7-4831-B27A-FEA83CC6B410Q40573306-11716601-5223-4F10-93E6-040150C27676Q44174733-5D8CC8E1-372C-4054-BF9C-9CDB91B806C9Q44400345-F45BDF65-198C-4C7F-B84E-4A65F558C19CQ44433507-4CAAFA21-1856-4D3A-817B-7020F7F383D3Q44977114-B5166B64-C217-4249-B412-37B0683D7B42
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Jeffrey L. Winters
@ast
Jeffrey L. Winters
@en
Jeffrey L. Winters
@es
Jeffrey L. Winters
@sl
type
label
Jeffrey L. Winters
@ast
Jeffrey L. Winters
@en
Jeffrey L. Winters
@es
Jeffrey L. Winters
@sl
prefLabel
Jeffrey L. Winters
@ast
Jeffrey L. Winters
@en
Jeffrey L. Winters
@es
Jeffrey L. Winters
@sl
P214
P244
P1053
A-2000-2013
P106
P1153
7102662786
P1960
56kIaccAAAAJ
P21
P214
P244
n2009183661
P31
P3829
P496
0000-0001-8654-3732
P734
P735
P7859
lccn-n2009183661